Over the past 12‑18 months the Constipation Laxative industry trends have been shaped by a wave of strategic activity. In March 2023, GSK entered a co‑development partnership with biotech start‑up Biosynex to combine GSK’s polyethylene glycol platform with Biosynex’s microbiome‑modulating technology, targeting faster‑acting, gut‑friendly laxatives. July 2023 saw Pfizer’s acquisition of niche OTC brand LaxAll for $420 million, expanding its presence in the North‑American over‑the‑counter segment. The same month, Viatris launched Relief‑Plus, a dual‑action chewable tablet that integrates a low‑dose stimulant with a prebiotic fiber, marking the first "fiber‑stimulus hybrid" on U.S. shelves. Regulatory momentum accelerated when the FDA issued revised labeling guidance in September 2023, mandating clearer dosage instructions for chronic‑use products, prompting manufacturers to reformulate packaging. Consumer behavior shifted toward "wellness‑first" self‑care, with a 22 % YoY rise in online purchases of natural‑origin laxatives reported by Nielsen. Finally, a €150 million Series B round closed for GutHarmony in early 2024, funding its expansion into European retail chains and a digital adherence platform. These moves collectively signal a more integrated, technology‑driven growth path for the market.
